A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19: bamlanivimab

Principal Investigator(s):  View help for Principal Investigator(s) Jens D Lundgren, Department of Infectious Diseases, Rigshospitalet, Copenhagan, Denmark

Version:  View help for Version V1

Name File Type Size Last Modified
LillyFormsPubUse.pdf application/pdf 665.8 KB 09/22/2023 09:21:AM
Table1.lst text/plain 4.2 KB 09/28/2023 10:35:AM
Table1.sas application/x-sas 838 bytes 09/22/2023 09:20:AM
Table2.lst text/plain 16.4 KB 09/22/2023 08:57:AM
Table2.sas application/x-sas 1.4 KB 09/22/2023 08:57:AM
lillypubusedoc.docx application/vnd.openxmlformats-officedocument.wordprocessingml.document 22.8 KB 09/27/2023 09:04:AM
ticopubliciaelilly.pdf application/pdf 26.4 KB 09/27/2023 09:09:AM
ticopubliciaelilly.sas7bdat application/x-sas-data 320 KB 09/22/2023 08:55:AM
ticopubliclilly.pdf application/pdf 61.4 KB 09/27/2023 09:09:AM
ticopubliclilly.sas7bdat application/x-sas-data 2.8 MB 09/27/2023 09:04:AM

Project Citation: 

Lundgren, Jens  D. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19: bamlanivimab . Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2023-10-24. https://doi.org/10.3886/E194685V1

Project Description

Summary:  View help for Summary This data comes from a randomized, international, double blind study comparing LY-CoV555 to standard of care for the primary outcome of sustained recovery during a 90-day period in hospitalized patients with COVID-19, carried out in Fall 2020. Participants were randomized 1:1 to receive either Ly-CoV555 or matching placebo. All patients received high-quality supportive care as background therapy, including the use of remdesivir.  A total of 314 patients were enrolled, 163 to LY-CoV555 and 151 to placebo. The rate ratio for sustained recovery was 1.06 (95% CI, 0.77 to 1.47).
Funding Sources:  View help for Funding Sources Operation Warp Speed)

Scope of Project

Subject Terms:  View help for Subject Terms Monoclonal Antibody; bamlanivimab; COVID-19; Randomized clinical trial; sustained recovery
Geographic Coverage:  View help for Geographic Coverage United States, Denmark
Time Period(s):  View help for Time Period(s) 8/1/2020 – 1/31/2021 (Fall 2020)
Collection Date(s):  View help for Collection Date(s) 8/1/2020 – 1/31/2021
Universe:  View help for Universe COVID-19 hospitalized patients age 18 and over
Data Type(s):  View help for Data Type(s) clinical data; program source code
Collection Notes:  View help for Collection Notes SAS datasets and item documentation

Methodology

Response Rate:  View help for Response Rate
Response rate was not collected. Only participants that consented had data collected.
Sampling:  View help for Sampling
Hospitalized patients with COVID-19
Data Source:  View help for Data Source Clinical trial database
Collection Mode(s):  View help for Collection Mode(s) coded on-site observation; face-to-face interview; other; telephone interview
Scales:  View help for Scales No scales used. Primary endpoint was sustained recovery; discharged to home and remaining home for 14 consecutive days.
Weights:  View help for Weights No weights used
Unit(s) of Observation:  View help for Unit(s) of Observation individuals
Geographic Unit:  View help for Geographic Unit person level

Related Publications

This study is un-published. See below for other available versions.

Published Versions

Export Metadata

Dublin Core

DDI 2.5

Report a Problem

Found a serious problem with the data, such as disclosure risk or copyrighted content? Let us know.

This material is distributed exactly as it arrived from the data depositor. ICPSR has not checked or processed this material. Users should consult the investigator(s) if further information is desired.